PFE - Pfizer's COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date FDA Revises Label | Benzinga
The FDA has updated the emergency use authorization (EUA) for Pfizer Inc’s (NYSE:PFE) Paxlovid, impacting its distribution and use in treating mild-to-moderate COVID-19.
In December 2021, the FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric patients who are at high risk for progression to severe COVID-19, including hospitalization or death.
In May 2023, the FDA approved Pfizer’s NDA for Paxlovid for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
According to the revised authorization, EUA-labeled Paxlovid currently in ...